Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Federal Trade Commission
Fuji
AstraZeneca
Baxter
Harvard Business School
Argus Health
Teva
Julphar

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DESLORATADINE

« Back to Dashboard

Clinical Trials for Desloratadine

Trial ID Title Status Sponsor Phase Summary
NCT00160537 POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis) Completed UCB Pharma Phase 4 Comparative study on clinical efficacy and safety of levocetirizine and desloratadine as measured by the subject's satisfaction/dissatisfaction after one week of treatment
NCT00160589 LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis) Completed UCB Pharma Phase 4 Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)
NCT00264303 CUTE (Chronic Urticaria Treatment Evaluation) Completed UCB Pharma Phase 4 A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over the first week of treatment
NCT00311844 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed Merck Sharp & Dohme Corp. Phase 4 This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis induced by direct conjunctival challenges with a previously identified sensitizing antigen, in the eyes of a subject known to be sensitive to the antigen.
NCT00346606 The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria Unknown status Lotus Pharmaceutical Phase 4 Objective: To compare the efficacy of desloratadine 5mg (Denosin®) and levocetirizine 5mg (Xyzal®) once daily in the treatment of patients with CIU over 6 weeks. Trial design: Randomized, Double-Blind, Active-Controlled, Parallel-Group Study. Primary end point: To evaluate the change in average AM/PM reflective pruritus score from baseline recorded in the subjects’ diaries during the first two weeks of the treatment. Secondary Objectives: To assess the efficacy and safety of desloratadine 5mg (Denosin®) and levocetirizine 5mg (Xyzal®) once daily in the treatment of subjects with CIU over 6 weeks.
NCT00359138 The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441) Completed Merck Sharp & Dohme Corp. Phase 4 This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class > 2) to one of the tested standardized allergenic extracts: tree pollen, cat dander, house dust mite, or a mixture of five grass pollens. Subjects will be randomized to desloratadine 5 mg once daily, levocetirizine 5mg once daily, or placebo once daily for 8 days of treatment followed by 11 days of skin testing after discontinuation of the antihistamine treatment phase. The duration of the suppressive effects of desloratadine on cutaneous allergen-induced wheal and flare responses after discontinuation of a one-week treatment will be established.
NCT00405964 Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684) Completed Merck Sharp & Dohme Corp. Phase 3 This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis (PER)
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Desloratadine

Condition Name

Condition Name for Desloratadine
Intervention Trials
Urticaria 10
Seasonal Allergic Rhinitis 9
Allergic Rhinitis 9
Chronic Idiopathic Urticaria 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Desloratadine
Intervention Trials
Rhinitis 26
Rhinitis, Allergic 25
Urticaria 17
Rhinitis, Allergic, Seasonal 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Desloratadine

Trials by Country

Trials by Country for Desloratadine
Location Trials
United States 8
Germany 6
Brazil 5
Canada 3
China 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Desloratadine
Location Trials
Florida 5
New Jersey 2
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Desloratadine

Clinical Trial Phase

Clinical Trial Phase for Desloratadine
Clinical Trial Phase Trials
Phase 4 25
Phase 3 21
Phase 2/Phase 3 1
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Desloratadine
Clinical Trial Phase Trials
Completed 53
Recruiting 4
Unknown status 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Desloratadine

Sponsor Name

Sponsor Name for Desloratadine
Sponsor Trials
Merck Sharp & Dohme Corp. 31
Dr. Reddy's Laboratories Limited 6
UCB Pharma 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Desloratadine
Sponsor Trials
Industry 53
Other 11
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Argus Health
Federal Trade Commission
Colorcon
Mallinckrodt
Moodys
Deloitte
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.